VRPXVirpax Pharmaceuticals, Inc.

Nasdaq virpaxpharma.com


$ 0.76 $ -0.01 (-1.01 %)    

Monday, 20-May-2024 15:59:49 EDT
QQQ $ 454.82 $ 3.15 (0.7 %)
DIA $ 398.57 $ -1.85 (-0.46 %)
SPY $ 530.36 $ 0.61 (0.12 %)
TLT $ 91.26 $ -0.27 (-0.3 %)
GLD $ 225.37 $ 0.90 (0.4 %)
$ 0.7731
$ 0.77
$ 0.00 x 0
$ 0.00 x 0
$ 0.75 - $ 0.77
$ 0.68 - $ 11.77
184,757
na
905,480
$ 0.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 12-07-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 virpax-announces-pricing-of-225m-public-offering

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing n...

 virpax-pharmaceuticals-announced-results-for-a-maximum-tolerated-dose-study-in-sprague-dawley-rats-for-probudur

Probudur is Virpax's injectable long-acting liposomal bupivacaine formulation that is injected at the wound site. Probudur ...

 on-april-2-virpax-pharmaceuticals-inc-got-letter-from-nasdaq-stating-that-company-was-not-in-compliance-with-nasdaq-listing-rule

- SEC Filing

Core News & Articles

As part of the settlement, the parties have agreed to a cash payment from Virpax to the Plaintiffs of $3.5 million by March 1, ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION